Loading
A phase 1/2 trial of AZD4360 in pancreatic ductal adenocarcinoma, run by AstraZeneca, active and no longer recruiting.
Study for AZD4360 in Participants With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06921928 by AstraZeneca, with 31 participants enrolled, started 2025-04-29 and due to reach its primary completion in 2027-03-31. Interventions recorded: AZD4360. Conditions listed: Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/